BioCardia Inc. (BCDA)
BioCardia Statistics
Share Statistics
BioCardia has 4.58M shares outstanding. The number of shares has increased by -82.85% in one year.
Shares Outstanding | 4.58M |
Shares Change (YoY) | -82.85% |
Shares Change (QoQ) | 30.91% |
Owned by Institutions (%) | 0.04% |
Shares Floating | 3.66M |
Failed to Deliver (FTD) Shares | 1.14K |
FTD / Avg. Volume | 2.28% |
Short Selling Information
The latest short interest is 86.28K, so 1.88% of the outstanding shares have been sold short.
Short Interest | 86.28K |
Short % of Shares Out | 1.88% |
Short % of Float | 2.27% |
Short Ratio (days to cover) | 1.41 |
Valuation Ratios
The PE ratio is -1.22 and the forward PE ratio is -1.87. BioCardia's PEG ratio is 0.06.
PE Ratio | -1.22 |
Forward PE | -1.87 |
PS Ratio | 29.48 |
Forward PS | 1.4 |
PB Ratio | -8.77 |
P/FCF Ratio | -1.41 |
PEG Ratio | 0.06 |
Enterprise Valuation
BioCardia Inc. has an Enterprise Value (EV) of 14.28M.
EV / Earnings | -1.23 |
EV / Sales | 29.94 |
EV / EBITDA | -1.24 |
EV / EBIT | -1.23 |
EV / FCF | -1.43 |
Financial Position
The company has a current ratio of 0.4, with a Debt / Equity ratio of -0.82.
Current Ratio | 0.4 |
Quick Ratio | 0.4 |
Debt / Equity | -0.82 |
Total Debt / Capitalization | -456.6 |
Cash Flow / Debt | -7.58 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 7.22% and return on capital (ROIC) is 4043.06%.
Return on Equity (ROE) | 7.22% |
Return on Assets (ROA) | -3.87% |
Return on Capital (ROIC) | 4043.06% |
Revenue Per Employee | $29,812.5 |
Profits Per Employee | $-723,187.5 |
Employee Count | 16 |
Asset Turnover | 0.16 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.1% in the last 52 weeks. The beta is 1.3, so BioCardia's price volatility has been higher than the market average.
Beta | 1.3 |
52-Week Price Change | -63.1% |
50-Day Moving Average | 2.28 |
200-Day Moving Average | 2.82 |
Relative Strength Index (RSI) | 56.9 |
Average Volume (20 Days) | 50.04K |
Income Statement
In the last 12 months, BioCardia had revenue of 477K and earned -11.57M in profits. Earnings per share was -8.19.
Revenue | 477K |
Gross Profit | -7.25M |
Operating Income | -11.64M |
Net Income | -11.57M |
EBITDA | -11.56M |
EBIT | -11.64M |
Earnings Per Share (EPS) | -8.19 |
Balance Sheet
The company has 1.1M in cash and 1.31M in debt, giving a net cash position of -212K.
Cash & Cash Equivalents | 1.1M |
Total Debt | 1.31M |
Net Cash | -212K |
Retained Earnings | -152.18M |
Total Assets | 6.27M |
Working Capital | 2.22M |
Cash Flow
In the last 12 months, operating cash flow was -9.97M and capital expenditures -12K, giving a free cash flow of -9.99M.
Operating Cash Flow | -9.97M |
Capital Expenditures | -12K |
Free Cash Flow | -9.99M |
FCF Per Share | -7.07 |
Margins
Gross margin is -1.52K%, with operating and profit margins of -2.44K% and -2.43K%.
Gross Margin | -1.52K% |
Operating Margin | -2.44K% |
Pretax Margin | -2.43K% |
Profit Margin | -2.43K% |
EBITDA Margin | -2.42K% |
EBIT Margin | -2.44K% |
FCF Margin | -2.09K% |
Dividends & Yields
BCDA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -325% |
FCF Yield | -86.32% |
Analyst Forecast
The average price target for BCDA is $25, which is 892.1% higher than the current price. The consensus rating is "Buy".
Price Target | $25 |
Price Target Difference | 892.1% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on May 30, 2024. It was a backward split with a ratio of 1:15.
Last Split Date | May 30, 2024 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -37.26 |
Piotroski F-Score | 2 |